Surface modification of diaspirin cross-linked hemoglobin (DCLHb) with chondroitin-4-sulfate derivatives. Part 1.
Synthetic methodology was developed for the preparation of chondrotin-4-sulfate reagents that could be specifically attached to the surface of diaspirin cross-linked hemoglobin (DCLHb), a chemically stabilized human hemoglobin. The surface-modified hemoglobin solutions had a significantly higher colloidal osmotic pressures (COP) than DCLHb. The P(50) of the modified DCLHb was dependent upon the reactive end group of the chondrotin-4-sulfate reagents that was used for the protein modification. Modification of DCLHb with the chondroitin-4-sulfate derivatives containing the maleimide end group 23 provided a hemoglobin with a P(50) value of 23 mmHg, while the P(50) of hemoglobins prepared from chondroitin-4-sulfate derivatives containing the aldehyde end group 13 and 18 remained unchanged from that of DCLHb.
Hai
T T
TT
Corporate Research and Technical Services, Baxter Healthcare Corporation, 25212 West State Route 120, Round Lake, Illinois 60073-9799, USA. ton_hai@baxter.com
Pereira
D E
DE
Nelson
D J
DJ
Catarello
J
J
Srnak
A
A
D001241:Aspirin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D001802:Blood Substitutes / Q000737:chemistry / Q000494:pharmacology; D002240:Carbohydrate Sequence; D002809:Chondroitin Sulfates / Q000737:chemistry* / Q000494:pharmacology*; D004903:Erythrocyte Aggregation / Q000187:drug effects; D006454:Hemoglobins / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D008969:Molecular Sequence Data; D013329:Structure-Activity Relationship; D013499:Surface Properties
D001802:Blood Substitutes; D006454:Hemoglobins; D002809:Chondroitin Sulfates; C083478:diaspirin-cross-linked hemoglobin; D001241:Aspirin